Empowered Patient Podcast
About
Available on
Community
1296 episodes
MELANIE SMITH, Senior Manager of learning and developing at Air Methods, was a US Army Black Hawk helicopter pilot. She now trains clinicians, emergency medicine experts, pilots, first responders, mechanics, and corporate officials to respond to critical care needs, natural disasters, and accidents. The training program includes hands-on exercises with a high-fidelity manikin that talks back and can throw up, gamification, and virtual reality to provide an immersive experience in different situations. Melanie elaborates, "I flew Black Hawks in the Army for 12 years. Five of those years were spent in combat in Iraq and Afghanistan and earthquake relief in Pakistan. After 12 years of service, I decided to get out of the military and join the civilian world. I still needed to serve my community. Instead of a life of service in the military, I wanted to serve my local community. So I joined Air Methods, and it really fulfilled that desire to help. I flew the line in Air Methods for 12 years, mostly North Carolina, flying all over the nation. Then I came to corporate Air Methods and decided to get into teaching." "Typically, to get into these roles, you have to have had some varied experience so that you're ready for it. Clinicians have to have an emergency room setting, emergency medicine, and maybe some ICU so that they can take care of every type of patient we would pick up. And then the pilots typically have a varied background as well. Maybe they were military, or maybe they flew all over the world. We have pilots from across the board. Maybe they flew in the jungle or in Alaska in the winter environment. We put all of our past experiences together and need it for every mission that we do now." #AirMethods #CriticalCare #ClinicalEducation #VR #CECredits #HealthcareCE #NursingCE #ParamedicCE #ClinicalCE #FlightClinician #CAPCE #CABRN #ClinicalSkills #ProfessionalDevelopment #DigitalHealth #RuralHealthcare AIRMETHODS.COM http://AirMethods.com LISTEN TO THE PODCAST HERE img http://AirMethods.com
MELANIE SMITH, Senior Manager of learning and developing at Air Methods, was a US Army Black Hawk helicopter pilot. She now trains clinicians, emergency medicine experts, pilots, first responders, mechanics, and corporate officials to respond to critical care needs, natural disasters, and accidents. The training program includes hands-on exercises with a high-fidelity manikin that talks back and can throw up, gamification, and virtual reality to provide an immersive experience in different situations. Melanie elaborates, "I flew Black Hawks in the Army for 12 years. Five of those years were spent in combat in Iraq and Afghanistan and earthquake relief in Pakistan. After 12 years of service, I decided to get out of the military and join the civilian world. I still needed to serve my community. Instead of a life of service in the military, I wanted to serve my local community. So I joined Air Methods, and it really fulfilled that desire to help. I flew the line in Air Methods for 12 years, mostly North Carolina, flying all over the nation. Then I came to corporate Air Methods and decided to get into teaching." "Typically, to get into these roles, you have to have had some varied experience so that you're ready for it. Clinicians have to have an emergency room setting, emergency medicine, and maybe some ICU so that they can take care of every type of patient we would pick up. And then the pilots typically have a varied background as well. Maybe they were military, or maybe they flew all over the world. We have pilots from across the board. Maybe they flew in the jungle or in Alaska in the winter environment. We put all of our past experiences together and need it for every mission that we do now." #AirMethods #CriticalCare #ClinicalEducation #VR #CECredits #HealthcareCE #NursingCE #ParamedicCE #ClinicalCE #FlightClinician #CAPCE #CABRN #ClinicalSkills #ProfessionalDevelopment #DigitalHealth #RuralHealthcare AIRMETHODS.COM http://AirMethods.com DOWNLOAD THE TRANSCRIPT HERE img http://AirMethods.com
DR. BETHANY DORAN, the CEO of Enabled Health, is using a healthcare model that identifies patients at high risk of hospitalization or who need help managing a chronic condition. With a focus on predominantly older patients, Enabled Health works with community partners and senior living facilities to allow patients access to remote monitoring systems, digital tools, and on-site visits. Bethany explains, "Our goal is to meet them where they are spiritually, holistically, and geographically and be able to provide them with the equipment to enable access to telemedicine and support their health. But also, to meet them in person, in some cases, and just be a good steward and guide to them on their healthcare journey." "We spend a good amount of time just listening to their medical history, how they've been doing, any challenges, and reconciling any medications they have. Then we also provide them with equipment to enable telemedicine and telemonitoring. They have a tablet that can either link to wifi, or in some cases, it's cellular, but allows the patient to engage in telemedicine as well for those times that we can't be in-person." "Going in-person to the assisted living facilities we work with, we'll go once per month in person and set them up for telemedicine for the rest of their visits. But we think it's really important to maintain our relationships with patients, just serving as a partner in health. Not relying only on telemedicine or telemonitoring and thinking that will fix everything about a patient's health, but be there as a true partner and use that as a tool to expand instead access for patients." #Telehealth #Telemedicine #ChronicDiseases #HealthEquity #RuralHealthcare #DigitalHealth #ChronicCareManagement #RemotePatientMonitoring ENABLED.HEALTHCARE http://enabled.healthcare LISTEN TO THE PODCAST HERE http://enabled.healthcare
DR. BETHANY DORAN, the CEO of Enabled Health, is using a healthcare model that identifies patients at high risk of hospitalization or who need help managing a chronic condition. With a focus on predominantly older patients, Enabled Health works with community partners and senior living facilities to allow patients access to remote monitoring systems, digital tools, and on-site visits. Bethany explains, "Our goal is to meet them where they are spiritually, holistically, and geographically and be able to provide them with the equipment to enable access to telemedicine and support their health. But also, to meet them in person, in some cases, and just be a good steward and guide to them on their healthcare journey." "We spend a good amount of time just listening to their medical history, how they've been doing, any challenges, and reconciling any medications they have. Then we also provide them with equipment to enable telemedicine and telemonitoring. They have a tablet that can either link to wifi, or in some cases, it's cellular, but allows the patient to engage in telemedicine as well for those times that we can't be in-person." "Going in-person to the assisted living facilities we work with, we'll go once per month in person and set them up for telemedicine for the rest of their visits. But we think it's really important to maintain our relationships with patients, just serving as a partner in health. Not relying only on telemedicine or telemonitoring and thinking that will fix everything about a patient's health, but be there as a true partner and use that as a tool to expand instead access for patients." #Telehealth #Telemedicine #ChronicDiseases #HealthEquity #RuralHealthcare #DigitalHealth #ChronicCareManagement #RemotePatientMonitoring ENABLED.HEALTHCARE http://enabled.healthcare DOWNLOAD THE TRANSCRIPT HERE http://enabled.healthcare
DAVID BEARSS the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components of chronic inflammation, such as Alzheimer's disease, heart disease, COPD, psoriasis, IBD, and cancer. Their potential drug target is the NLRP3 inflammasome which has been identified as being associated with the activation of inflammation. David explains, "We've gotten better and better at trying to narrow down on how we can block these inflammatory responses. But there's just been, in the past few years, a real explosion in our knowledge of what the root drivers of chronic inflammation are. At Halia, we're focused on trying to take out the root cause, not some of the downstream effects or the signaling molecules, but take out the responsible thing, the machine inside the cell that's activated, that's propagating these signals. If we can turn that off, we think we can get to the root cause of what's driving these problems and all these different diseases." "It's just in the past few years that we've discovered that there are these cellular machines that get formed under the right conditions that help propagate or signal this inflammatory response. We call those machines inflammasomes, and there are five that we know of. There are probably a few more that are what we call non-canonical inflammasomes. But the inflammasomes have been a really hot area of research in lots of different diseases to try to understand how these protein complexes get formed inside cells and how they stay stuck on in chronic inflammation." @Halia_Tx #ChronicInflammation #Immunity #Neuroscience #AlzheimersDisease #InflammatoryDisease #DrugDevelopment #Biotech HALIATHERAPEUTICS.COM http://haliatherapeutics.com LISTEN TO THE PODCAST HERE
DAVID BEARSS the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components of chronic inflammation, such as Alzheimer's disease, heart disease, COPD, psoriasis, IBD, and cancer. Their potential drug target is the NLRP3 inflammasome which has been identified as being associated with the activation of inflammation. David explains, "We've gotten better and better at trying to narrow down on how we can block these inflammatory responses. But there's just been, in the past few years, a real explosion in our knowledge of what the root drivers of chronic inflammation are. At Halia, we're focused on trying to take out the root cause, not some of the downstream effects or the signaling molecules, but take out the responsible thing, the machine inside the cell that's activated, that's propagating these signals. If we can turn that off, we think we can get to the root cause of what's driving these problems and all these different diseases." "It's just in the past few years that we've discovered that there are these cellular machines that get formed under the right conditions that help propagate or signal this inflammatory response. We call those machines inflammasomes, and there are five that we know of. There are probably a few more that are what we call non-canonical inflammasomes. But the inflammasomes have been a really hot area of research in lots of different diseases to try to understand how these protein complexes get formed inside cells and how they stay stuck on in chronic inflammation." @Halia_Tx #ChronicInflammation #Immunity #Neuroscience #AlzheimersDisease #InflammatoryDisease #DrugDevelopment #Biotech HALIATHERAPEUTICS.COM http://haliatherapeutics.com DOWNLOAD THE TRANSCRIPT HERE
DR. TINA ALBERTSON is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells. Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors." " I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional." "The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient." #Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy LYELL.COM LISTEN TO THE PODCAST HERE http://lyell.com
DR. TINA ALBERTSON is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells. Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors." " I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional." "The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient." #Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy LYELL.COM DOWNLOAD THE TRANSCRIPT HERE http://lyell.com
SAM LEE is the Co-CEO and President of Cocrystal Pharma, focused on pandemic viruses and seasonal influenza to develop a drug that is cross-spectrum with a high barrier to drug resistance. Using computational data, as well as high-resolution X-ray data, their platform allows options for newly emerging viruses that also address potency and combination treatment options. Sam explains, "We just completed the Phase I study. In the Phase I study, we demonstrated the favorable safety and tolerability of this compound, CC-42344. We designed this compound for pandemic and seasonal influenza A infection. Particularly, this compound is highly sensitive to the avian influenza strain, potentially an emerging pandemic strain." "I think with antiviral drug development, you always have to think about three important things. One is the cross-spectrum, which covers the existing viruses. For example, in the influenza case, influenza H1N1, H2, and H3. And beyond seasonal influenza viruses are pandemic viruses, H5 and H7, and potentially emerging avian flu. So we want to cover all these viruses. That's a really important goal." "Once you achieve good potency and cross-spectrum activity, then you want to solve the pharmacology. It's going to be a once-a-day drug with the excellent drug resistance. Drug resistance is a really key contribution using our platform approach. " @CocrystalPharma $COCP #PandemicFlu #CC42344 #SeasonalInfluenzaA #Flu #Pandemic COCRYSTALPHARMA.COM http://CocrystalPharma.com LISTEN TO THE PODCAST HERE img http://CocrystalPharma.com
SAM LEE is the Co-CEO and President of Cocrystal Pharma, focused on pandemic viruses and seasonal influenza to develop a drug that is cross-spectrum with a high barrier to drug resistance. Using computational data, as well as high-resolution X-ray data, their platform allows options for newly emerging viruses that also address potency and combination treatment options. Sam explains, "We just completed the Phase I study. In the Phase I study, we demonstrated the favorable safety and tolerability of this compound, CC-42344. We designed this compound for pandemic and seasonal influenza A infection. Particularly, this compound is highly sensitive to the avian influenza strain, potentially an emerging pandemic strain." "I think with antiviral drug development, you always have to think about three important things. One is the cross-spectrum, which covers the existing viruses. For example, in the influenza case, influenza H1N1, H2, and H3. And beyond seasonal influenza viruses are pandemic viruses, H5 and H7, and potentially emerging avian flu. So we want to cover all these viruses. That's a really important goal." "Once you achieve good potency and cross-spectrum activity, then you want to solve the pharmacology. It's going to be a once-a-day drug with the excellent drug resistance. Drug resistance is a really key contribution using our platform approach. " @CocrystalPharma $COCP #PandemicFlu #CC42344 #SeasonalInfluenzaA #Flu #Pandemic COCRYSTALPHARMA.COM http://CocrystalPharma.com DOWNLOAD THE TRANSCRIPT HERE img http://CocrystalPharma.com
GABRIEL MECKLENBURG is the Co-Founder and Executive Chairman at Hinge Health, the leading digital clinic for back, joint, and muscle pain. Hinge provides personalized physical therapy plans by pairing digital and advanced motion-tracking technology with clinical care teams, including doctors, nurses, physical therapists, and board-certified health coaches. Recognizing the value of in-person care, Hinge is rolling out an in-home option to meet the needs of a wide variety of patients. Gabriel explains, "Now, with Hinge Health, it's a digital program, and it's something that you can immediately access from the convenience of your home. You're getting an assessment of your condition right then and there. You can get started on clinically proven exercise therapy, education, coaching, PT type therapies immediately. It's a personalized, highly-tailored program for each individual, which, again, is very similar for a market-wide experience." "We're excited to branch into what we call hybrid care, combining the best of both worlds of in-person and digital care. Our physical therapy house call service is a fully-integrated digital and in-person care experience for back, joint, and muscle health." "The reason why we're pursuing this is that many Americans of all ages prefer to have an option of in-person visits alongside the digital health experience. In particular, for the kinds of conditions that we are tackling, in-person evaluations for joint and muscle pain can substantially enhance the experience and the quality of downstream digital care." #HingeHealth #MSK #Musculoskeletal #DigitalHealth #PT #PhysicalTherapy #HealthandWellness #ChronicPain #HybridPT #VirtualPT #HomeHealthcare #HomeHealth HINGEHEALTH.COM http://hingehealth.com LISTEN TO THE PODCAST HERE
GABRIEL MECKLENBURG is the Co-Founder and Executive Chairman at Hinge Health, the leading digital clinic for back, joint, and muscle pain. Hinge provides personalized physical therapy plans by pairing digital and advanced motion-tracking technology with clinical care teams, including doctors, nurses, physical therapists, and board-certified health coaches. Recognizing the value of in-person care, Hinge is rolling out an in-home option to meet the needs of a wide variety of patients. Gabriel explains, "Now, with Hinge Health, it's a digital program, and it's something that you can immediately access from the convenience of your home. You're getting an assessment of your condition right then and there. You can get started on clinically proven exercise therapy, education, coaching, PT type therapies immediately. It's a personalized, highly-tailored program for each individual, which, again, is very similar for a market-wide experience." "We're excited to branch into what we call hybrid care, combining the best of both worlds of in-person and digital care. Our physical therapy house call service is a fully-integrated digital and in-person care experience for back, joint, and muscle health." "The reason why we're pursuing this is that many Americans of all ages prefer to have an option of in-person visits alongside the digital health experience. In particular, for the kinds of conditions that we are tackling, in-person evaluations for joint and muscle pain can substantially enhance the experience and the quality of downstream digital care." #HingeHealth #MSK #Musculoskeletal #DigitalHealth #PT #PhysicalTherapy #HealthandWellness #ChronicPain #HybridPT #VirtualPT #HomeHealthcare #HomeHealth HINGEHEALTH.COM http://hingehealth.com DOWNLOAD THE TRANSCRIPT HERE
DR. PAUL LAMMERS, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells. At the forefront of the next generation of immune-oncology, Triumvira uses the Cocoon Platform made by Lonza to automate this process in a closed system to grow and harvest the cells. The ultimate goal is to have this technology available at the point of care in regional cancer centers to allow this cell therapy to be used by more cancer patients. Paul elaborates, "The challenge with T cell therapy has been can we also use cell therapy to treat solid tumors? And that's where we feel that with our technology, known as TAC, T Cell Antigen Coupler comes in. We truly think we have an opportunity here, so we feel we are developing first-in-class medications based on that new T cell engineer platform, the TAC. We hope to have an opportunity to focus on different types of targets in solid tumors that will address high unmet needs in cancers like gastric cancer and colorectal cancer and pancreatic cancer, and ovarian and endometrial." "Our first program is in the clinic targeting HER2, which is a well-known target, especially for breast cancer and also gastric cancer. But we're expanding that. In the second half of this year, we're starting a first clinical trial targeting claudin 18.2, which is an exciting new upcoming target in different solid tumors, especially for gastric, pancreatic, and gastroesophageal cancer. Followed then in the next two years by new targets known as GUCY2C, which is a great target for colorectal cancer, and GPC3, a target for primary liver cancer. So it's an exciting time to build a broad and strong pipeline based on that TAC technology platform." #Triumvira #TCells #TCellTherapy #TAC #Cancer #SolidTumorCancer #CellTherapy #BreastCancer #GastricCancer TRIUMVIRA.COM http://Triumvira.com LISTEN TO THE PODCAST HERE img
DR. PAUL LAMMERS, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells. At the forefront of the next generation of immune-oncology, Triumvira uses the Cocoon Platform made by Lonza to automate this process in a closed system to grow and harvest the cells. The ultimate goal is to have this technology available at the point of care in regional cancer centers to allow this cell therapy to be used by more cancer patients. Paul elaborates, "The challenge with T cell therapy has been can we also use cell therapy to treat solid tumors? And that's where we feel that with our technology, known as TAC, T Cell Antigen Coupler comes in. We truly think we have an opportunity here, so we feel we are developing first-in-class medications based on that new T cell engineer platform, the TAC. We hope to have an opportunity to focus on different types of targets in solid tumors that will address high unmet needs in cancers like gastric cancer and colorectal cancer and pancreatic cancer, and ovarian and endometrial." "Our first program is in the clinic targeting HER2, which is a well-known target, especially for breast cancer and also gastric cancer. But we're expanding that. In the second half of this year, we're starting a first clinical trial targeting claudin 18.2, which is an exciting new upcoming target in different solid tumors, especially for gastric, pancreatic, and gastroesophageal cancer. Followed then in the next two years by new targets known as GUCY2C, which is a great target for colorectal cancer, and GPC3, a target for primary liver cancer. So it's an exciting time to build a broad and strong pipeline based on that TAC technology platform." #Triumvira #TCells #TCellTherapy #TAC #Cancer #SolidTumorCancer #CellTherapy #BreastCancer #GastricCancer TRIUMVIRA.COM http://Triumvira.com DOWNLOAD THE TRANSCRIPT HERE img
TOMER SHUSSMAN, CEO of OneStep, is combining in-person physical therapy and in-person care with remote care to provide more accessible healthcare, improve clinical outcomes, and enable clinicians to generate additional revenue streams. The OneStep smartphone app continuously monitors how patients move and analyzes over 40 different gait parameters. Working with providers, such as physical therapy clinics and orthopedic surgeons, OneStep has entered into the orthotic and prosthetic fields, translating these parameters into actual clinical insights. Tomer explains, "So the main two or three things we've launched in the last year was one, a fall risk model. So we are now able to tell the user whether they are at a fall risk. I think we're the first ones in the world that have a model that makes sense in the sense that we're not just telling you, "Hey. you are at a high risk of falling," but we're telling you, "The system has recognized that some of your gait parameters have shifted in a way that is associated with a higher risk of falling. So we see that you're taking 10% narrower steps and 15% shorter steps. You're spending a bit too much time on your left leg, and this all has been associated with a fall risk." "We have developed similar programs for amputees in the field of prosthetics, supporting the fine-tuning of the prosthetics and making sure they're installed properly. We've done similar things for upper body and lower back pain, where providers use OneStep to help triage patients and understand which patients can be transitioned to remote care and which patients can't. This is what OneStep has been focused on in the last year." @DigitalOneStep #OneStep #GaitAnalysis #FallRiskAssessment #HealthTech #RTM #ChoosePT #PhysicalTherapy #Telehealth #HealthCareInnovation #Prosthetics #Amputees ONESTEP.CO LISTEN TO THE PODCAST HERE http://onestep.co
TOMER SHUSSMAN, CEO of OneStep, is combining in-person physical therapy and in-person care with remote care to provide more accessible healthcare, improve clinical outcomes, and enable clinicians to generate additional revenue streams. The OneStep smartphone app continuously monitors how patients move and analyzes over 40 different gait parameters. Working with providers, such as physical therapy clinics and orthopedic surgeons, OneStep has entered into the orthotic and prosthetic fields, translating these parameters into actual clinical insights. Tomer explains, "So the main two or three things we've launched in the last year was one, a fall risk model. So we are now able to tell the user whether they are at a fall risk. I think we're the first ones in the world that have a model that makes sense in the sense that we're not just telling you, "Hey. you are at a high risk of falling," but we're telling you, "The system has recognized that some of your gait parameters have shifted in a way that is associated with a higher risk of falling. So we see that you're taking 10% narrower steps and 15% shorter steps. You're spending a bit too much time on your left leg, and this all has been associated with a fall risk." "We have developed similar programs for amputees in the field of prosthetics, supporting the fine-tuning of the prosthetics and making sure they're installed properly. We've done similar things for upper body and lower back pain, where providers use OneStep to help triage patients and understand which patients can be transitioned to remote care and which patients can't. This is what OneStep has been focused on in the last year." @DigitalOneStep #OneStep #GaitAnalysis #FallRiskAssessment #HealthTech #RTM #ChoosePT #PhysicalTherapy #Telehealth #HealthCareInnovation #Prosthetics #Amputees ONESTEP.CO DOWNLOAD THE TRANSCRIPT HERE http://onestep.co
ANGIE FRANKS is the CEO of ABOUT Healthcare, focusing on care orchestration for patients needing acute, post-acute, and transitional care. ABOUT works with healthcare systems to use technology to replace many phone calls and manual work to allow for a smoother process of identifying appropriate and available facilities. This approach also impacts networks of referral sources, making it easier for health systems to build stronger relationships with consistent processes and standards. Angie explains, "When we're talking about a physician seeking the right setting of care for the patient, that process is filled with friction. It's filled with friction because when they're calling and contacting a facility, calling an inpatient facility to see if they can accept another patient, the people that are answering those calls don't have the information that they need at their fingertips to be able to make the decision." "When we come in and help health systems put in place the right technology, what we're doing is changing the workflow. We put in place some best practices in terms of operational processes. Then we enable that with technology to structure a decision-making process so that the people that receive that call have all of the information they need to be able to make a decision and execute on that decision. This takes what can be a multi-hour process and turn that into something that is 15 to 30 minutes." @ABOUT_est2005 #ABOUTHealth #CareOrchestration #PatientFlow #PatientOutcomes #CareNavigation #PatientTransfers #PatientAccess ABOUTHEALTHCARE.COM http:/abouthealthcare.com LISTEN TO THE PODCAST HERE http://empoweredpatientradio.com/predicting-and-managing-acute-care-demand-and-throughput-process-with-angie-franks-about-healthcare img
ANGIE FRANKS is the CEO of ABOUT Healthcare, focusing on care orchestration for patients needing acute, post-acute, and transitional care. ABOUT works with healthcare systems to use technology to replace many phone calls and manual work to allow for a smoother process of identifying appropriate and available facilities. This approach also impacts networks of referral sources, making it easier for health systems to build stronger relationships with consistent processes and standards. Angie explains, "When we're talking about a physician seeking the right setting of care for the patient, that process is filled with friction. It's filled with friction because when they're calling and contacting a facility, calling an inpatient facility to see if they can accept another patient, the people that are answering those calls don't have the information that they need at their fingertips to be able to make the decision." "When we come in and help health systems put in place the right technology, what we're doing is changing the workflow. We put in place some best practices in terms of operational processes. Then we enable that with technology to structure a decision-making process so that the people that receive that call have all of the information they need to be able to make a decision and execute on that decision. This takes what can be a multi-hour process and turn that into something that is 15 to 30 minutes." @ABOUT_est2005 #ABOUTHealth #CareOrchestration #PatientFlow #PatientOutcomes #CareNavigation #PatientTransfers #PatientAccess ABOUTHEALTHCARE.COM http:/abouthealthcare.com DOWNLOAD THE TRANSCRIPT HERE img
LAUREN OHLSSON is the lead of industry solutions for pharmaceutical and healthcare at VDX.tv, which partners with pharmaceutical marketing teams, healthcare advertisers, and media agencies to create video content that drives engagement with patients and healthcare personnel. They create custom interactive video ad units seen across Connected TVs, desktop computers, and mobile devices and targeted to the desired patients or providers. Using QR codes on CTV and OTT ads allows viewers to scan the code to get additional information quickly. Lauren explains, "One of the specific propositions we add is that we focus on CTV and then extend that reach to the household after that. It's a unique way to start these conversations around the household because often there are caretakers, family members, and a lot of people involved in medical decisions, so that's one of the facets of what VDX.tv can do." "We can do everything by targeting medical professionals by their NPI numbers. So if there's a specific chart list of doctors or medical professionals to reach, we can help do that. And then, we can target by conditions, so whether or not somebody has the probability of potentially having a medical condition, we can also reach them." "The environment is unique because we can target potential and prospective patients and healthcare providers via CTV. And then, to have the conversation with the household, we're able to follow up on desktops. So if you're engaging in health content, we'll take health.com, for example, you can see our ads, our video ads, in that environment as well, and then the same on a mobile device." "We know in pharma, the marketing teams are very focused on an omnichannel approach. We have an advantage in that we can reach people on their TVs, and then also on their mobile and desktop devices to make sure that we're distributing appropriate content to the right audiences." #VDXtv #DTCAds #HCPAds #HealthCarePersonnelAds #CTV #OTT #PharmaceuticalAds #HealthcareAds #MobileAds #PatientEngagement VDX.TV LISTEN TO THE PODCAST HERE http://vdx.tv
LAUREN OHLSSON is the lead of industry solutions for pharmaceutical and healthcare at VDX.tv, which partners with pharmaceutical marketing teams, healthcare advertisers, and media agencies to create video content that drives engagement with patients and healthcare personnel. They create custom interactive video ad units seen across Connected TVs, desktop computers, and mobile devices and targeted to the desired patients or providers. Using QR codes on CTV and OTT ads allows viewers to scan the code to get additional information quickly. Lauren explains, "One of the specific propositions we add is that we focus on CTV and then extend that reach to the household after that. It's a unique way to start these conversations around the household because often there are caretakers, family members, and a lot of people involved in medical decisions, so that's one of the facets of what VDX.tv can do." "We can do everything by targeting medical professionals by their NPI numbers. So if there's a specific chart list of doctors or medical professionals to reach, we can help do that. And then, we can target by conditions, so whether or not somebody has the probability of potentially having a medical condition, we can also reach them." "The environment is unique because we can target potential and prospective patients and healthcare providers via CTV. And then, to have the conversation with the household, we're able to follow up on desktops. So if you're engaging in health content, we'll take health.com, for example, you can see our ads, our video ads, in that environment as well, and then the same on a mobile device." "We know in pharma, the marketing teams are very focused on an omnichannel approach. We have an advantage in that we can reach people on their TVs, and then also on their mobile and desktop devices to make sure that we're distributing appropriate content to the right audiences." #VDXtv #DTCAds #HCPAds #HealthCarePersonnelAds #CTV #OTT #PharmaceuticalAds #HealthcareAds #MobileAds #PatientEngagement VDX.TV DOWNLOAD THE TRANSCRIPT HERE http://vdx.tv
SHANE BISHOP, the Founder and Chief Pharmacy Officer of Custom Health, aims for true medication adherence by providing multiple drugs in multi-dose strips in a manner that strongly encourages patients to stick with their medication regimen. Pharmacists and clinicians communicating with patients on a regular basis using a digital device gain a better understanding of side effects and other reasons people are not taking their medicine. A fully integrated medication management system makes an enormous difference in the quality of life, particularly for complex patients who require a wide variety of drugs. Shane elaborates, "Now, where we differentiate ourselves from others that are trying to accomplish the same type of thing to drive medication adherence through different packaging formats, we have a medication dispensing device that sits in a patient home where it drives medication adherence by beeping, whistling and flashing at the time of administration." "The patient touches the screen and out pops one of those multi-dose strip packages and relays that information live back to our pharmacies in our network, the pharmacies we own and operate, and our clinical pharmacist team where we have up to 500 clinical pharmacists at any given time to look at the data. We also drive patient-reported outcome data." "Our device also connects to the peripheral devices via Bluetooth connection. We can actually look at the vital information driven from glucometers, blood pressure monitors, and weight scales." #CustomHealth #HealthCare #DigitalHealth #MedicationAdherence #Pharmacy #HomeBasedCare #Technology CUSTOMHEALTH.COM http://customhealth.com LISTEN TO THE PODCAST HERE img http://customhealth.com
SHANE BISHOP, the Founder and Chief Pharmacy Officer of Custom Health, aims for true medication adherence by providing multiple drugs in multi-dose strips in a manner that strongly encourages patients to stick with their medication regimen. Pharmacists and clinicians communicating with patients on a regular basis using a digital device gain a better understanding of side effects and other reasons people are not taking their medicine. A fully integrated medication management system makes an enormous difference in the quality of life, particularly for complex patients who require a wide variety of drugs. Shane elaborates, "Now, where we differentiate ourselves from others that are trying to accomplish the same type of thing to drive medication adherence through different packaging formats, we have a medication dispensing device that sits in a patient home where it drives medication adherence by beeping, whistling and flashing at the time of administration." "The patient touches the screen and out pops one of those multi-dose strip packages and relays that information live back to our pharmacies in our network, the pharmacies we own and operate, and our clinical pharmacist team where we have up to 500 clinical pharmacists at any given time to look at the data. We also drive patient-reported outcome data." "Our device also connects to the peripheral devices via Bluetooth connection. We can actually look at the vital information driven from glucometers, blood pressure monitors, and weight scales." #CustomHealth #HealthCare #DigitalHealth #MedicationAdherence #Pharmacy #HomeBasedCare #Technology CUSTOMHEALTH.COM http://customhealth.com DOWNLOAD THE TRANSCRIPT HERE img http://customhealth.com
MARIA ZANNES, Founder and CEO of bioAffinity Technologies, has developed a noninvasive diagnostic test to screen for early-stage lung cancer. The test uses porphyrin to label cells to find cell populations with cancer cells. Using mucus from the lungs, this is a second test for people who are at high risk, giving them a chance to avoid more invasive procedures to determine their risk level and if they have lung cancer. Maria explains, "The combination of being able to determine that cancer is present in the lungs with our test, coupled with the noninvasive nature of the test itself really spoke to me. Having a test for early detection of lung cancer where the treatment can be so much more effective and people can live so much longer and healthier lives is compelling." "It's very simple for the patient and the doctor. The patient would go in, let's say they had a positive low-dose CT, they weren't sure, and the physician would then give the patient a small box. It's a 5x5 box with a little collection cup inside. We have a patient coach, an individual who calls the patient, and helps them to provide a sample, often early in the morning. People out of a shower start to cough up a little bit of mucus." "The results tell the physician whether the patient is at high risk or has lung cancer or does not, but also gives them a numerical score, so the physician himself or herself has a little bit more to go on than just a yes or no answer." @bioAffinity #LungCancer #CancerDiagnostic #Medtech #Biotech #CancerTreatment #CancerDiagnosis BIOAFFINITYTECH.COM http://bioaffinitytech.com LISTEN TO THE PODCAST HERE img
MARIA ZANNES, Founder and CEO of bioAffinity Technologies, has developed a noninvasive diagnostic test to screen for early-stage lung cancer. The test uses porphyrin to label cells to find cell populations with cancer cells. Using mucus from the lungs, this is a second test for people who are at high risk, giving them a chance to avoid more invasive procedures to determine their risk level and if they have lung cancer. Maria explains, "The combination of being able to determine that cancer is present in the lungs with our test, coupled with the noninvasive nature of the test itself really spoke to me. Having a test for early detection of lung cancer where the treatment can be so much more effective and people can live so much longer and healthier lives is compelling." "It's very simple for the patient and the doctor. The patient would go in, let's say they had a positive low-dose CT, they weren't sure, and the physician would then give the patient a small box. It's a 5x5 box with a little collection cup inside. We have a patient coach, an individual who calls the patient, and helps them to provide a sample, often early in the morning. People out of a shower start to cough up a little bit of mucus." "The results tell the physician whether the patient is at high risk or has lung cancer or does not, but also gives them a numerical score, so the physician himself or herself has a little bit more to go on than just a yes or no answer." @bioAffinity #LungCancer #CancerDiagnostic #Medtech #Biotech #CancerTreatment #CancerDiagnosis BIOAFFINITYTECH.COM http://bioaffinitytech.com DOWNLOAD THE TRANSCRIPT HERE img
DR. ROBERT RISINGER is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. Their fast-acting sublingual film formulation is an advancement over the current regime of intramuscular injections. The drug is also being studied for agitation related to Alzheimer's disease and at-home use to reduce the number of people who go to the emergency room for untreated agitation. Rob explains, "For example, the medication, the active pharmaceutical ingredient dexmedetomidine, was used, for years, as an IV anesthetic. At very high doses, it can produce a level of sleep or sedation so patients can undergo surgery and medical procedures. But our algorithms identified the fact that this may affect the core causal mechanism, this kind of fight or flight reaction, that we believe is responsible for causing agitation in humans and, specifically, in patients with bipolar disorder and schizophrenia." "The molecule itself has physical-chemical properties that allow it to get into the body quickly. We can use, essentially, very, very low doses compared to what is typically given for anesthesia purposes. So we tested this out systematically and came up with a new form and formulation, a sublingual film with mucoadhesive properties. And that allows us to diminish the agitation in patients experiencing these symptoms. The molecule itself has physical-chemical properties that allow it to get into the body quickly. We can use, essentially, very, very low doses compared to what is typically given for anesthesia purposes. So we tested this out systematically and came up with a new form and formulation, a sublingual film with mucoadhesive properties. And that allows us to diminish the agitation in patients experiencing these symptoms." @BioXcel #Neuroscience #Schizophrenia #BipolarDisorder #AlzheimersDisease #Agitation #AcuteAgitation BIOXCELTHERAPEUTICS.COM http://bioXcelTherapeutics.com LISTEN TO THE PODCAST HERE
DR. ROBERT RISINGER is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. Their fast-acting sublingual film formulation is an advancement over the current regime of intramuscular injections. The drug is also being studied for agitation related to Alzheimer's disease and at-home use to reduce the number of people who go to the emergency room for untreated agitation. Rob explains, "For example, the medication, the active pharmaceutical ingredient dexmedetomidine, was used, for years, as an IV anesthetic. At very high doses, it can produce a level of sleep or sedation so patients can undergo surgery and medical procedures. But our algorithms identified the fact that this may affect the core causal mechanism, this kind of fight or flight reaction, that we believe is responsible for causing agitation in humans and, specifically, in patients with bipolar disorder and schizophrenia." "The molecule itself has physical-chemical properties that allow it to get into the body quickly. We can use, essentially, very, very low doses compared to what is typically given for anesthesia purposes. So we tested this out systematically and came up with a new form and formulation, a sublingual film with mucoadhesive properties. And that allows us to diminish the agitation in patients experiencing these symptoms. The molecule itself has physical-chemical properties that allow it to get into the body quickly. We can use, essentially, very, very low doses compared to what is typically given for anesthesia purposes. So we tested this out systematically and came up with a new form and formulation, a sublingual film with mucoadhesive properties. And that allows us to diminish the agitation in patients experiencing these symptoms." @BioXcel #Neuroscience #Schizophrenia #BipolarDisorder #AlzheimersDisease #Agitation #AcuteAgitation BIOXCELTHERAPEUTICS.COM http://bioXcelTherapeutics.com DOWNLOAD THE TRANSCRIPT HERE
NEAL KOLLER is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected by this disease are ages 2 to 11 though it is a lifelong recurring problem with only a multi-drug treatment regimen available. Neal explains, "I think we've got three advantages. First, the plant material that we're using is the microbial and small molecule defense liquid of the plant, and so it's got a number of different bioactive compounds. One advantage for us is in our drug product, we have multiple bioactive compounds, which target a disease, in our case, atopic dermatitis, in different ways. So we have multiple ways we can attack and treat the disease. That's unique and different, having multiple ways, versus a standard drug generally only has one bioactive compound and one way to treat a disease." "The second advantage is that by using the plant-derived material in the way in which we're using it, we've had a faster path, and faster progress through our work to get to human clinical trials. That's primarily because our material, our drug substance, has a very, very strong safety profile." "Then the third advantage so far, unless, of course, the FDA changes this, is that because our drug product is plant-derived, there isn't a generic drug approval path. You, at the moment, still can't go into the lab, mix up some chemistry experiments, keep it simple, and say, "My chemistry is similar to Alphyn's chemistry, so please give me approval." #AlphynBiologics #AtopicDermatitis #Dermatology #SkinDisease ALPHYNBIOLOGICS.COM http://AlphynBiologics.com LISTEN TO THE PODCAST HERE http://AlphynBiologics.com
NEAL KOLLER is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected by this disease are ages 2 to 11 though it is a lifelong recurring problem with only a multi-drug treatment regimen available. Neal explains, "I think we've got three advantages. First, the plant material that we're using is the microbial and small molecule defense liquid of the plant, and so it's got a number of different bioactive compounds. One advantage for us is in our drug product, we have multiple bioactive compounds, which target a disease, in our case, atopic dermatitis, in different ways. So we have multiple ways we can attack and treat the disease. That's unique and different, having multiple ways, versus a standard drug generally only has one bioactive compound and one way to treat a disease." "The second advantage is that by using the plant-derived material in the way in which we're using it, we've had a faster path, and faster progress through our work to get to human clinical trials. That's primarily because our material, our drug substance, has a very, very strong safety profile." "Then the third advantage so far, unless, of course, the FDA changes this, is that because our drug product is plant-derived, there isn't a generic drug approval path. You, at the moment, still can't go into the lab, mix up some chemistry experiments, keep it simple, and say, "My chemistry is similar to Alphyn's chemistry, so please give me approval." #AlphynBiologics #AtopicDermatitis #Dermatology #SkinDisease ALPHYNBIOLOGICS.COM http://AlphynBiologics.com DOWNLOAD THE TRANSCRIPT HERE http://AlphynBiologics.com
BRETT FURST, President of HHS Technology Group, is carrying on the mission of efforts started at the beginning of the COVID outbreak to collaboratively share data to provide insights to those doing research, drug development, and addressing the impact of the pandemic on vulnerable populations. Maintaining this world's largest COVID database, HTG allows research on complex social determinants of health and how to address health equity. Brett explains, "So we were proud to take it on and be chosen by the consortium. Today we have the largest COVID research database in the world, with over 65 billion records. It touches almost 100% of our population in the United States. We're looking at all encounters from claims and clinical data, but also other more important for predictive modeling like social determinant data. We're trying to be more thoughtful about what's the next thing that's going to hit us out of the blue. We cannot be caught so flat-footed as we were in 2020." "There are concerns about long-term effects on those with Alzheimer's or other types of dementia, COPD, and breathing. I think what we all learned during this collaborative is that it didn't deflate everybody's competitive advantage and that sometimes regulations and rules can keep the market from actually advancing." @HHSTechnologyGroup #HHSTechGroup #HealthTech #HealthCare #COVID #LongCOVID #Pandemic #HealthData #HealthEquity #SDOH HHSTECHGROUP.COM http:/hhstechgroup.com LISTEN TO THE PODCAST HERE img http:/hhstechgroup.com
BRETT FURST, President of HHS Technology Group, is carrying on the mission of efforts started at the beginning of the COVID outbreak to collaboratively share data to provide insights to those doing research, drug development, and addressing the impact of the pandemic on vulnerable populations. Maintaining this world's largest COVID database, HTG allows research on complex social determinants of health and how to address health equity. Brett explains, "So we were proud to take it on and be chosen by the consortium. Today we have the largest COVID research database in the world, with over 65 billion records. It touches almost 100% of our population in the United States. We're looking at all encounters from claims and clinical data, but also other more important for predictive modeling like social determinant data. We're trying to be more thoughtful about what's the next thing that's going to hit us out of the blue. We cannot be caught so flat-footed as we were in 2020." "There are concerns about long-term effects on those with Alzheimer's or other types of dementia, COPD, and breathing. I think what we all learned during this collaborative is that it didn't deflate everybody's competitive advantage and that sometimes regulations and rules can keep the market from actually advancing." @HHSTechnologyGroup #HHSTechGroup #HealthTech #HealthCare #COVID #LongCOVID #Pandemic #HealthData #HealthEquity #SDOH HHSTECHGROUP.COM http:/hhstechgroup.com DOWNLOAD THE TRANSCRIPT HERE img http:/hhstechgroup.com
